
|Videos|January 16, 2023
Dr. Ravi highlights ongoing trials of PSMA-targeted agents in prostate cancer
Author(s)Urology Times staff
“There are a slew of ongoing trials looking at 177Lu-PSMA-617 in earlier stages of disease,” says Praful Ravi, MB, BChir, MRCP.
Advertisement
Praful Ravi, MB, BChir, MRCP,discusses trials exploring PSMA-targeted therapy at earlier disease stages and in combination regimens in patients with prostate cancer. Ravi is a medical oncologist at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5


















